MTOR and hepatocellular carcinoma: In addition, KEGG-MTOR-signaling-pathway was activated by NR6A1 as well as UNC119B, and KEGG-NOTCH-signaling-pathway was activated by OSBP2. All of these signals were significantly relevant to HCC tumorigenesis, progression, metastasis, and therapy resistance, suggesting that targeting Kla might impair the activation of these pathways, thereby inhibiting HCC development and elevating the therapy response.